Page last updated: 2024-11-04

sulfanilamide and Acquired Immune Deficiency Syndrome

sulfanilamide has been researched along with Acquired Immune Deficiency Syndrome in 1 studies

Research Excerpts

ExcerptRelevanceReference
"The preferred therapeutic regimen for Toxoplasma encephalitis (TE) is a combination of pyrimethamine and sulfadiazine, and trimethoprim-sulfamethoxazole (TMP-SMX) plus azithromycin is the widespread alternative therapeutic regimen."9.51Synergistic sulfonamides plus clindamycin as an alternative therapeutic regimen for HIV-associated Toxoplasma encephalitis: a randomized controlled trial. ( Chen, H; Chen, Y; He, X; Huang, Y; Li, Y; Lu, Y; Wu, Y; Zeng, Y; Zhang, W, 2022)
"The preferred therapeutic regimen for Toxoplasma encephalitis (TE) is a combination of pyrimethamine and sulfadiazine, and trimethoprim-sulfamethoxazole (TMP-SMX) plus azithromycin is the widespread alternative therapeutic regimen."5.51Synergistic sulfonamides plus clindamycin as an alternative therapeutic regimen for HIV-associated Toxoplasma encephalitis: a randomized controlled trial. ( Chen, H; Chen, Y; He, X; Huang, Y; Li, Y; Lu, Y; Wu, Y; Zeng, Y; Zhang, W, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Li, Y1
Zeng, Y1
Lu, Y1
He, X1
Wu, Y1
Zhang, W1
Huang, Y1
Chen, H1
Chen, Y1

Trials

1 trial available for sulfanilamide and Acquired Immune Deficiency Syndrome

ArticleYear
Synergistic sulfonamides plus clindamycin as an alternative therapeutic regimen for HIV-associated Toxoplasma encephalitis: a randomized controlled trial.
    Chinese medical journal, 2022, Nov-20, Volume: 135, Issue:22

    Topics: Acquired Immunodeficiency Syndrome; Azithromycin; Clindamycin; Encephalitis; Humans; Sulfadiazine; S

2022